Ország: Szingapúr
Nyelv: angol
Forrás: HSA (Health Sciences Authority)
METHYLPREDNISOLONE SODIUM SUCCINATE EQV METHYLPREDNISOLONE
PFIZER PRIVATE LIMITED
H02AB04
500 mg/8 ml
INJECTION, POWDER, FOR SOLUTION
METHYLPREDNISOLONE SODIUM SUCCINATE EQV METHYLPREDNISOLONE 500 mg/8 ml
INTRAVENOUS, INTRAMUSCULAR
Prescription Only
PFIZER MANUFACTURING BELGIUM NV
ACTIVE
1990-06-13
SOLU-MEDROL TABLE OF CONTENT _Please click on either of the following links to access the required information:_ PRESCRIBING INFORMATION PATIENT INFORMATION LEAFLET 1. NAME OF THE MEDICINAL PRODUCT SOLU-MEDROL 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient: Methylprednisolone Sodium Succinate. Methylprednisolone Sodium Succinate is available for IV or IM administration as: VIAL (MAY BE PACKAGED WITH A DILUENT) 500 mg/8 mL Vial containing methylprednisolone sodium succinate equivalent to 500 mg methylprednisolone. 1 g/16 mL Vial containing methylprednisolone sodium succinate equivalent to 1 g methylprednisolone. 2 g/32 mL Vial containing methylprednisolone sodium succinate equivalent to 2 g methylprednisolone. Not all strengths may be available locally. 3. PHARMACEUTICAL FORM Sterile powder for injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Methylprednisolone sodium succinate is indicated in the following conditions: ENDOCRINE DISORDERS primary or secondary adrenocortical insufficiency (in conjunction with mineralocorticoids, where applicable); acute adrenocortical insufficiency (mineralocorticoid supplementation may be necessary); shock secondary to adrenocortical insufficiency, or shock unresponsive to conventional therapy when adrenal cortical insufficiency may be present (when mineralocorticoid activity is undesirable); pre-operatively, or in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful; congenital adrenal hyperplasia; non-suppurative thyroiditis; hypercalcemia associated with cancer. RHEUMATIC DISORDERS (as adjunctive therapy for short-term administration in the management of an acute episode or exacerbation) post-traumatic osteoarthritis; synovitis of osteoarthritis; Page 1 of 9 rheumatoid arthritis, including juvenile rheumatoid arthritis; acute and subacute bursitis; epicondylitis; acute non-specific tenosynovitis; acute gouty arthritis; Olvassa el a teljes dokumentumot
SOLU-MEDROL TABLE OF CONTENT _Please click on either of the following links to access the required information:_ PRESCRIBING INFORMATION PATIENT INFORMATION LEAFLET Page 1 of 19 1. NAME OF THE MEDICINAL PRODUCT SOLU-MEDROL 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient: Methylprednisolone Sodium Succinate. Methylprednisolone Sodium Succinate is available for IV or IM administration as: VIAL (MAY BE PACKAGED WITH A DILUENT) 500 mg/8 mL Vial containing methylprednisolone sodium succinate equivalent to 500 mg methylprednisolone. 1 g/16 mL Vial containing methylprednisolone sodium succinate equivalent to 1 g methylprednisolone. 2 g/32 mL Vial containing methylprednisolone sodium succinate equivalent to 2 g methylprednisolone. Not all strengths may be available locally. 3. PHARMACEUTICAL FORM Sterile powder for injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Methylprednisolone sodium succinate is indicated in the following conditions: ENDOCRINE DISORDERS primary or secondary adrenocortical insufficiency (in conjunction with mineralocorticoids, where applicable); acute adrenocortical insufficiency (mineralocorticoid supplementation may be necessary); shock secondary to adrenocortical insufficiency, or shock unresponsive to conventional therapy when adrenal cortical insufficiency may be present (when mineralocorticoid activity is undesirable); pre-operatively, or in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful; congenital adrenal hyperplasia; non-suppurative thyroiditis; hypercalcemia associated with cancer. RHEUMATIC DISORDERS (as adjunctive therapy for short-term administration in the management of an acute episode or exacerbation) post-traumatic osteoarthritis; synovitis of osteoarthritis; Page 2 of 19 rheumatoid arthritis, including juvenile rheumatoid arthritis; acute and subacute bursitis; epicondylitis; acute non-specific tenosynovitis; acute gout Olvassa el a teljes dokumentumot